Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2h-1-benzopyran-2-one
2. Aldocumar
3. Apo-warfarin
4. Coumadin
5. Coumadine
6. Gen-warfarin
7. Marevan
8. Potassium, Warfarin
9. Sodium, Warfarin
10. Tedicumar
11. Warfant
12. Warfarin
13. Warfarin Potassium
1. 129-06-6
2. Sodium Warfarin
3. Jantoven
4. Aldocumar
5. Athrombin
6. Marevan
7. Zoocoumarin Sodium Salt
8. Warfarin Sodium Salt
9. Apo-warfarin
10. Warfarin (sodium)
11. Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-2h-chromen-4-olate
12. Warfarin Sodium [usp]
13. 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin Sodium Salt
14. 6153cwm0cl
15. Warfarin Sodium Clathrate
16. 2h-1-benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, Sodium Salt
17. 67430-45-9
18. Coumadine
19. Dicusat
20. Marevam
21. Orfarin
22. Tintorane
23. Varfine
24. Warcoumin
25. Warfarin Sodium (usp)
26. Warfilone
27. Simarc
28. Coumadin Sodium
29. Sodium Coumadin
30. Uniwarfin
31. Ratsul Soluble
32. Coumadan Sodico
33. Coumafene Sodium
34. Warfarinsodium
35. Sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate
36. Warfarin, Sodium Salt
37. Caswell No. 903a
38. Warfarin-sodium
39. (+-)-warfarin Sodium
40. Warfarin, Sodium Deriv.
41. Einecs 204-929-4
42. 3-(3-oxo-1-phenylbutyl)-4-sodiooxy-2h-1-benzopyran-2-one
43. Epa Pesticide Chemical Code 086003
44. Unii-6153cwm0cl
45. Warfarinum Natricum
46. Coumadin (tn)
47. Jantoven (tn)
48. Einecs 226-909-4
49. Sodium, ((3-(alpha-acetonylbenzyl)-2-oxo-2h-1-benzopyran-4-yl)oxy)-
50. Warfarin Sodium Clatharate
51. Schembl7826
52. Dsstox_cid_15010
53. Dsstox_rid_79236
54. Dsstox_gsid_35010
55. Mls001074341
56. Warfarin Sodium [vandf]
57. Chembl1200879
58. Dtxsid7035010
59. Warfarin Sodium [mart.]
60. Hy-b0687a
61. Warfarin Sodium [who-dd]
62. Warfarin Sodium [who-ip]
63. Warfarin Sodium Salt [mi]
64. Coumarin, 3-(alpha-acetonylbenzyl)-4-hydroxy-, Sodium Salt
65. Hms2233p10
66. Hms3259g13
67. Hms3369m10
68. Bcp20702
69. Tox21_301545
70. Bdbm50248297
71. Warfarin Sodium [orange Book]
72. Akos015951251
73. Akos015955387
74. Warfarin Sodium [ep Monograph]
75. Ac-8078
76. Cs-w019743
77. Nc00490
78. Warfarin Sodium [usp Monograph]
79. Ncgc00255556-01
80. Ac-19972
81. Cas-129-06-6
82. Smr000058849
83. Warfarinum Natricum [who-ip Latin]
84. W0005
85. Warfarin Sodium (contains Isopropyl Alcohol)
86. D00564
87. O12075
88. A805899
89. J-005647
90. Sodium Warfarin;warf42 Sodium; Athrombine-k Sodium
91. Q27263296
92. 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin Sodiuim Salt
93. 4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin Sodium Salt
94. Sodium 2-oxo-3-(3-oxo-1-phenylbutyl)-1-benzopyran-4-olate
95. 3-(.alpha.-acetonylbenzyl)-4-hydroxycoumarin Sodium Salt
96. Sodium 2-oxidanylidene-3-(3-oxidanylidene-1-phenyl-butyl)chromen-4-olate
97. 2h-1-benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, Sodium Salt (1:1)
| Molecular Weight | 330.3 g/mol |
|---|---|
| Molecular Formula | C19H15NaO4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 4 |
| Exact Mass | 330.08680324 g/mol |
| Monoisotopic Mass | 330.08680324 g/mol |
| Topological Polar Surface Area | 66.4 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 508 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Jantoven |
| PubMed Health | Warfarin |
| Drug Classes | Anticoagulant |
| Drug Label | JantovenTablets (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an isopropan... |
| Active Ingredient | Warfarin sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2.5mg; 7.5mg; 1mg; 5mg; 4mg; 6mg; 2mg; 10mg; 3mg |
| Market Status | Prescription |
| Company | Usl Pharma |
| 2 of 4 | |
|---|---|
| Drug Name | Warfarin sodium |
| Drug Label | Warfarin sodium tablet (crystalline warfarin sodium) is an anticoagulant, which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an i... |
| Active Ingredient | Warfarin sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2.5mg; 7.5mg; 1mg; 5mg; 4mg; 6mg; 2mg; 10mg; 3mg |
| Market Status | Prescription |
| Company | Amneal Pharms; Taro; Invagen Pharms; Ipca Labs; Zydus Pharms Usa; Pliva; Mylan; Barr |
| 3 of 4 | |
|---|---|
| Drug Name | Jantoven |
| PubMed Health | Warfarin |
| Drug Classes | Anticoagulant |
| Drug Label | JantovenTablets (crystalline warfarin sodium) is an anticoagulant which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an isopropan... |
| Active Ingredient | Warfarin sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2.5mg; 7.5mg; 1mg; 5mg; 4mg; 6mg; 2mg; 10mg; 3mg |
| Market Status | Prescription |
| Company | Usl Pharma |
| 4 of 4 | |
|---|---|
| Drug Name | Warfarin sodium |
| Drug Label | Warfarin sodium tablet (crystalline warfarin sodium) is an anticoagulant, which acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(and is a racemic mixture of the R- and S-enantiomers. Crystalline warfarin sodium is an i... |
| Active Ingredient | Warfarin sodium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 2.5mg; 7.5mg; 1mg; 5mg; 4mg; 6mg; 2mg; 10mg; 3mg |
| Market Status | Prescription |
| Company | Amneal Pharms; Taro; Invagen Pharms; Ipca Labs; Zydus Pharms Usa; Pliva; Mylan; Barr |
Anticoagulants
Agents that prevent BLOOD CLOTTING. (See all compounds classified as Anticoagulants.)
Rodenticides
Substances used to destroy or inhibit the action of rats, mice, or other rodents. (See all compounds classified as Rodenticides.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22132
Submission : 2008-11-11
Status : Active
Type : II
NDC Package Code : 63278-1058
Start Marketing Date : 1983-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12269
Submission : 1996-12-16
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-03-09
Pay. Date : 2014-12-31
DMF Number : 28925
Submission : 2014-12-31
Status : Active
Type : II
Certificate Number : R0-CEP 2015-059 - Rev 00
Issue Date : 2016-12-02
Type : Chemical
Substance Number : 698
Status : Withdrawn by Holder

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23289
Submission : 2009-11-20
Status : Active
Type : II
Date of Issue : 2025-09-29
Valid Till : 2028-09-28
Written Confirmation Number : WC-0305
Address of the Firm :

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21925
Submission : 2008-08-25
Status : Active
Type : II
Date of Issue : 2024-07-31
Valid Till : 2027-01-24
Written Confirmation Number : WC-0291
Address of the Firm :

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36406
Submission : 2021-10-14
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12746
Submission : 1997-11-18
Status : Active
Type : II
Certificate Number : R1-CEP 2001-285 - Rev 05
Issue Date : 2017-08-24
Type : Chemical
Substance Number : 698
Status : Valid

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21926
Submission : 2008-08-25
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12117
Submission : 1996-08-27
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Amlitelimab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Amlitelimab,Midazolam,Caffeine,Metoprolol Tartrate,Omeprazole,Warfarin Sodium
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 13, 2024
Lead Product(s) : Amlitelimab,Midazolam,Caffeine,Metoprolol Tartrate,Omeprazole,Warfarin Sodium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amlitelimab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 13, 2024
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colitis, Ulcerative.
Lead Product(s): Risankizumab,Midazolam,Caffeine,Warfarin Sodium,Vitamin K1,Omeprazole,Metoprolol Tartrate
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2020
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Risankizumab,Midazolam,Caffeine,Warfarin Sodium,Vitamin K1,Omeprazole,Metoprolol Tartrate
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Risankizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 05, 2020
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GZR18 is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Lead Product(s): GZR18,Digoxin,Rosuvastatin Calcium,Warfarin Sodium
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GZR18,Digoxin,Rosuvastatin Calcium,Warfarin Sodium
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
Details : GZR18 is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 19, 2025

Details:
Repaglinide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Repaglinide,Warfarin Sodium,Omeprazole,Y-3
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 16, 2025

Lead Product(s) : Repaglinide,Warfarin Sodium,Omeprazole,Y-3
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Y-3 on Repaglinide, Warfarin & Omeprazole in Healthy
Details : Repaglinide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Radiprodil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Tuberous Sclerosis.
Lead Product(s): Radiprodil,Warfarin Sodium,Midazolam,Digoxin,Rosuvastatin Calcium,Omeprazole,Vitamin K1
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Avance Clinical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Radiprodil,Warfarin Sodium,Midazolam,Digoxin,Rosuvastatin Calcium,Omeprazole,Vitamin K1
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Open-Label DDI Study of Radiprodil with Co-Administered Drugs
Details : Radiprodil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Tuberous Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Lead Product(s): Paracetamol,Metformin,Warfarin Sodium,BGM0504
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Paracetamol,Metformin,Warfarin Sodium,BGM0504
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BGM0504 in Overweight or Obese Participants
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 09, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Warfarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Warfarin Sodium,Enlicitide Decanoate,Lisinopril
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Warfarin Sodium,Enlicitide Decanoate,Lisinopril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Warfarin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2025

Details:
Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): Paracetamol,Metformin,Warfarin Sodium,Atorvastatin,Digoxin,HRS9531
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024

Lead Product(s) : Paracetamol,Metformin,Warfarin Sodium,Atorvastatin,Digoxin,HRS9531
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024

Details:
Edoxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atrial Fibrillation.
Lead Product(s): Edoxaban Tosylate,Warfarin Sodium
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Daiichi Sankyo
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 07, 2024

Lead Product(s) : Edoxaban Tosylate,Warfarin Sodium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Daiichi Sankyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Edoxaban is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
XW003 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): XW003,Metformin,Warfarin Sodium,Rosuvastatin Calcium,Digoxin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : XW003,Metformin,Warfarin Sodium,Rosuvastatin Calcium,Digoxin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
Details : XW003 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 28, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Lennon Warfarin
Dosage Form : TAB
Dosage Strength : 5mg
Packaging : 100X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : Canada
Brand Name :
Dosage Form : TABLET
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number : 40616
Regulatory Info : Generic
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : Canada
Brand Name :
Dosage Form : TABLET
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 11771
Regulatory Info : Generic
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : Canada
Brand Name :
Dosage Form : TABLET
Dosage Strength : 3MG
Packaging :
Approval Date :
Application Number : 200104
Regulatory Info : Generic
Registration Country : Canada
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Norway
Brand Name : Warfarin Orion
Dosage Form : Antic-calc Tablet
Dosage Strength : 2.5 mg
Packaging : Box of plastic
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Warfarin Orion
Dosage Form : Tablet
Dosage Strength : 2.5mg
Packaging :
Approval Date : 27/08/2010
Application Number : 20090803000035
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info :
Registration Country : India
Brand Name : Warfarin Sodium
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : COUMADIN
Dosage Form : TABLET;ORAL
Dosage Strength : 10MG
Packaging :
Approval Date : 1982-01-01
Application Number : 9218
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : COUMADIN
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Packaging :
Approval Date : 1982-01-01
Application Number : 9218
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : COUMADIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 75MG/VIAL
Packaging :
Approval Date : 1982-01-01
Application Number : 9218
Regulatory Info : DISCN
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Dosage Form : Granule / Pellet, Tablet
Grade : Oral
Category : Fillers, Diluents & Binders, Granulation, Solubilizers
Application : Fillers, Diluents & Binders, Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Application : Fillers, Diluents & Binders
Excipient Details : KoVidone® K25 is used as a low viscosity wet binder in solid dosage forms such as capsules and tablets.
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Injectable / Parenteral, Tablet
Grade : Parenteral, Oral
Category : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Application : Fillers, Diluents & Binders, Parenteral, Thickeners and Stabilizers
Excipient Details : D-Mannitol protects proteins from denaturation & degradation. It is used as a stabilizer in liquid products including biologic injectables & vaccines.
Pharmacopoeia Ref : USP, EP, BP, JP, ChP
Technical Specs : Low Endotoxin, Low Metals
Ingredient(s) : Mannitol
Dosage Form : Orodispersible Tablet, Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Direct Compression, Fillers, Diluents & Binders, Taste Masking
Dosage Form : Tablet, Orodispersible Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Application : Chewable & Orodispersible Aids, Co-Processed Excipients, Direct Compression, Disintegrants & Superdisintegrants, Fillers, Diluents & Binders, Taste Masking
Excipient Details : Advantol® 300 is a DC pharmaceutical excipient used to create soft chew or fast melt oral dosage forms through co-processing technology.
Grade : Oral
Category : Co-Processed Excipients, Fillers, Diluents & Binders
Application : Co-Processed Excipients, Fillers, Diluents & Binders
Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.
Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...
Technical Specs : NA
Ingredient(s) : Microcrystalline Cellulose Excipients
Application : Co-Processed Excipients, Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
97
PharmaCompass offers a list of Warfarin Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Warfarin Sodium manufacturer or Warfarin Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Warfarin Sodium manufacturer or Warfarin Sodium supplier.
PharmaCompass also assists you with knowing the Warfarin Sodium API Price utilized in the formulation of products. Warfarin Sodium API Price is not always fixed or binding as the Warfarin Sodium Price is obtained through a variety of data sources. The Warfarin Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Warfarin Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Warfarin Sodium, including repackagers and relabelers. The FDA regulates Warfarin Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Warfarin Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Warfarin Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Warfarin Sodium supplier is an individual or a company that provides Warfarin Sodium active pharmaceutical ingredient (API) or Warfarin Sodium finished formulations upon request. The Warfarin Sodium suppliers may include Warfarin Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Warfarin Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Warfarin Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Warfarin Sodium active pharmaceutical ingredient (API) in detail. Different forms of Warfarin Sodium DMFs exist exist since differing nations have different regulations, such as Warfarin Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Warfarin Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Warfarin Sodium USDMF includes data on Warfarin Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Warfarin Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Warfarin Sodium suppliers with USDMF on PharmaCompass.
A Warfarin Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Warfarin Sodium Certificate of Suitability (COS). The purpose of a Warfarin Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Warfarin Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Warfarin Sodium to their clients by showing that a Warfarin Sodium CEP has been issued for it. The manufacturer submits a Warfarin Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Warfarin Sodium CEP holder for the record. Additionally, the data presented in the Warfarin Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Warfarin Sodium DMF.
A Warfarin Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Warfarin Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Warfarin Sodium suppliers with CEP (COS) on PharmaCompass.
A Warfarin Sodium written confirmation (Warfarin Sodium WC) is an official document issued by a regulatory agency to a Warfarin Sodium manufacturer, verifying that the manufacturing facility of a Warfarin Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Warfarin Sodium APIs or Warfarin Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Warfarin Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Warfarin Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Warfarin Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Warfarin Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Warfarin Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Warfarin Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Warfarin Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Warfarin Sodium suppliers with NDC on PharmaCompass.
Warfarin Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Warfarin Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Warfarin Sodium GMP manufacturer or Warfarin Sodium GMP API supplier for your needs.
A Warfarin Sodium CoA (Certificate of Analysis) is a formal document that attests to Warfarin Sodium's compliance with Warfarin Sodium specifications and serves as a tool for batch-level quality control.
Warfarin Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Warfarin Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Warfarin Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Warfarin Sodium EP), Warfarin Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Warfarin Sodium USP).